Reduction of body iron stores and the prevention of type 2 diabetes.
Mascitelli
Luca
L
Pezzetta
Francesca
F
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D019440:Anti-Obesity Agents / Q000627:therapeutic use; D001815:Bloodletting; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D004032:Diet; D015444:Exercise; D018149:Glucose Intolerance / Q000150:complications* / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007501:Iron / Q000097:blood*; D008019:Life Style
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D019440:Anti-Obesity Agents; D007004:Hypoglycemic Agents; D007501:Iron